
    
      -  Each treatment cycle lasts 4 weeks during which time the study drug will be administered
           for three consecutive weeks followed by 1 week of no study drug. STA-9090 will be given
           by intravenous infusion.

        -  Participants will come to the clinic on Days 1, 8, and 15 of all cycles. At these
           visits, the following tests and procedures will be performed: Review of current
           medications and any side effects experienced; Performance status evaluation; Physical
           examination; Vital signs; Routine blood tests; CT scan of the chest, abdomen, and pelvis
           (every 2 cycles) and Optional FDG-PET scan (every 2 cycles).

        -  Participants may remain on this research study for as long as their cancer is responding
           to the study drug and they are not experiencing any severe side effects.
    
  